Get 40% Off
🚀 Our AI Picked 6 Stocks that Jumped +25% in Q1. Which Picks Will Soar in Q2?Unlock full list

ANALYSIS-Thoratec likely to target early-stage developers

Published 08/24/2009, 01:54 PM
Updated 08/24/2009, 01:57 PM

* World Heart, Abiomed among potential targets * Co itself seen as a target for larger players By Anuradha Ramanathan

BANGALORE, Aug 24 (Reuters) - After a failed attempt at buying a rival with a potentially superior product, cardiac-device maker Thoratec Corp will likely look to buy an early-stage product developer or diversify into other heart device areas.

Thoratec itself could also become an acquisition target for other device makers, mainly due to its potential to serve some heart-failure patients who cannot undergo transplants.

The merger deal with Australia's HeartWare International Inc -- which could have allowed Thoratec to jump a couple of steps in the technology curve -- was nixed by U.S. regulators last month on antitrust concerns.

"(Thoratec) has about $300 million in the bank and it is not earning them any money. I think they want to put it to use," SMH Capital analyst Suraj Kalia said.

Privately owned cardiac device makers such as New Jersey-based Circulite Inc, Levitronics Inc and World Heart Corp could be among the potential acquisition targets for Thoratec, analysts said.

Although these products are in the nascent stages of study, Wedbush Morgan Securities analyst Duane Nash said that he "would not be surprised" if Thoratec jumped in and bought one of these early stage products and improved on it.

Last week, World Heart received a conditional approval from the U.S. health regulators to begin a clinical study of its magnetically levitated implantable heart pump.

Greg Simpson, analyst with Stifel Nicolaus, said Abiomed Inc, which focuses on acute heart failure, could also be of "interest" to Thoratec, whose products cater to more chronic heart condition.

Thoratec's left ventricular assist devices (LVADs) are needed by patients with severe congestive heart failure with few medical options, whereas Abiomed's catheter-based pumps are used to provide circulatory support for periods of up to 6 hours.

And with HeartWare now seen as a legitimate competitor, any bid for Abiomed or an early stage developer would probably attract less antitrust scrutiny.


Analysts identified Medtronic Inc, Johnson and Johnson Inc and Boston Scientific Inc as possible Thoratec acquirers.

Though, Garp Research & Securities Co analyst Alastair Mackay said big conglomerates also run the risk of overpaying for Thoratec.

The shares have risen about 13 percent this year to $27.82. At those levels, the stock is trading at about 35 times forward earnings compared with a sector average of about 20.

"Theoretically, Thoratec would be the first option (for would-be acquirers). It is going to be in the destination therapy market by early next year, which is the Holy Grail," SMH Capital's Kalia said.

Destination therapy refers to the use of ventricular assist devices as a long-term alternative to cardiac transplants.

Garp Research's Mackay said that of 75,000 U.S. patients who needs a new heart, only about 3000 are on the transplant list -- leaving a huge potential market for destination therapy.

Thoratec's HeartMate II device is currently being tested for safety and efficacy on advanced heart-failure patients who do not qualify for a heart transplant.

"Could (this cardiovascular space) ultimately be a $1 billion or $2 billion market? I think the answer is absolutely yes. There is no shortage of patients who could benefit from these devices," Stifel's Simpson said. (Reporting by Anuradha Ramanathan; Editing by Anthony Kurian)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.